tetano
Editor, Senior Moderator
J Glob Infect Dis
. 2022 Feb 17;14(1):24-30.
doi: 10.4103/jgid.jgid_96_21. eCollection Jan-Mar 2022.
Epitope Identification and Designing a Potent Multi-epitope Vaccine Construct against SARS-CoV-2 Including the Emerging Variants
Sivasubramanian Srinivasan[SUP] 1 [/SUP], Gracy Fathima Selvaraj[SUP] 1 [/SUP], Vidya Gopalan[SUP] 1 [/SUP], Padmapriya Padmanabhan[SUP] 1 [/SUP], Kiruba Ramesh[SUP] 1 [/SUP], Karthikeyan Govindan[SUP] 1 [/SUP], Aswathi Chandran[SUP] 1 [/SUP], Prabu Dhandapani[SUP] 2 [/SUP], Kaveri Krishnasamy[SUP] 1 [/SUP], Satish Srinivas Kitambi[SUP] 3 [/SUP]
Affiliations
Abstract
Introduction: The emergence of a novel coronavirus in China has turned into a SARS-CoV-2 pandemic with high fatality. As vaccines are developed through various strategies, their immunogenic potential may drastically vary and thus pose several challenges in offering immune responses against the virus.
Methods: In this study, we adopted an immunoinformatics-aided approach for developing a new multi-epitope vaccine construct (MEVC). In silico approach was taken for the identification of B-cell and T-cell epitopes in the Spike protein, for MEVC various cytotoxic T-lymphocyte, helper T-lymphocyte, and B-cell epitopes with the highest affinity for the respective HLA alleles were assembled and joined by linkers.
Results: The computational data suggest that the MEVC is nontoxic, nonallergenic and thermostable and elicit both humoral and cell-mediated immune responses. Subsequently, the biological activity of MEVC was assessed by bioinformatic tools using the interaction between the vaccine candidate and the innate immune system receptors TLR3 and TLR4. The epitopes of the construct were analyzed with that of the strains belonging to various clades including the emerging variants having multiple unique mutations in S protein.
Conclusions: Due to the advantageous features, the MEVC can be tested in vitro for more practical validation and the study offers immense scope for developing a potential vaccine candidate against SARS-CoV-2 in view of the public health emergency associated with COVID-19 disease caused by SARS-CoV-2.
Keywords: Epitopes; SARS-CoV-2; peptide antigen; prophylaxis; spike protein; vaccine.
. 2022 Feb 17;14(1):24-30.
doi: 10.4103/jgid.jgid_96_21. eCollection Jan-Mar 2022.
Epitope Identification and Designing a Potent Multi-epitope Vaccine Construct against SARS-CoV-2 Including the Emerging Variants
Sivasubramanian Srinivasan[SUP] 1 [/SUP], Gracy Fathima Selvaraj[SUP] 1 [/SUP], Vidya Gopalan[SUP] 1 [/SUP], Padmapriya Padmanabhan[SUP] 1 [/SUP], Kiruba Ramesh[SUP] 1 [/SUP], Karthikeyan Govindan[SUP] 1 [/SUP], Aswathi Chandran[SUP] 1 [/SUP], Prabu Dhandapani[SUP] 2 [/SUP], Kaveri Krishnasamy[SUP] 1 [/SUP], Satish Srinivas Kitambi[SUP] 3 [/SUP]
Affiliations
- PMID: 35418729
- PMCID: PMC8996455
- DOI: 10.4103/jgid.jgid_96_21
Abstract
Introduction: The emergence of a novel coronavirus in China has turned into a SARS-CoV-2 pandemic with high fatality. As vaccines are developed through various strategies, their immunogenic potential may drastically vary and thus pose several challenges in offering immune responses against the virus.
Methods: In this study, we adopted an immunoinformatics-aided approach for developing a new multi-epitope vaccine construct (MEVC). In silico approach was taken for the identification of B-cell and T-cell epitopes in the Spike protein, for MEVC various cytotoxic T-lymphocyte, helper T-lymphocyte, and B-cell epitopes with the highest affinity for the respective HLA alleles were assembled and joined by linkers.
Results: The computational data suggest that the MEVC is nontoxic, nonallergenic and thermostable and elicit both humoral and cell-mediated immune responses. Subsequently, the biological activity of MEVC was assessed by bioinformatic tools using the interaction between the vaccine candidate and the innate immune system receptors TLR3 and TLR4. The epitopes of the construct were analyzed with that of the strains belonging to various clades including the emerging variants having multiple unique mutations in S protein.
Conclusions: Due to the advantageous features, the MEVC can be tested in vitro for more practical validation and the study offers immense scope for developing a potential vaccine candidate against SARS-CoV-2 in view of the public health emergency associated with COVID-19 disease caused by SARS-CoV-2.
Keywords: Epitopes; SARS-CoV-2; peptide antigen; prophylaxis; spike protein; vaccine.